GSK acquires Nuvalent for $10.6B

GSK plc>>> has agreed to acquire GSK plc>>>, a US cancer drug firm, for $10.6 billion (£8 billion) in an all-cash deal. This acquisition, GSK plc>>>'s largest in over a decade, aims to significantly expand its oncology portfolio, particularly in lung cancer treatments. GSK plc>>> brings two experimental lung cancer treatments, zidesamtinib and neladalkib, which are in late-stage development and under review by the United States — Food and Drug Administration>>>. GSK plc>>> CEO Luke Miels>>> stated that these products are potential 'best-in-class assets' that could launch this year if approved, offering new treatment options for non-small cell lung cancer patients. The deal is expected to add to GSK plc>>>'s revenue growth from 2027 and support its target of over £40 billion in sales by 2031, helping to offset the looming patent expiration of its HIV drug Dolutegravir>>>. The transaction, which values GSK plc>>> at approximately $124 per share (a 40% premium), is expected to complete in the third quarter of 2026 and will be financed through existing and new debt facilities alongside cash reserves.